Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cardiometabolic diseases

What the SELECT trial of semaglutide means for clinicians

Accumulating data support the systemic benefits of semaglutide (and potentially other GLP-1RA-based therapies) in people with obesity, meaning that cardiologists and other clinicians must become familiar with prescribing them — particularly once market competition makes these drugs more accessible.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Broad benefits of semaglutide.

References

  1. Lincoff, A. M. et al. N. Engl. J. Med. 389, 2221–2232 (2023).

    Article  CAS  PubMed  Google Scholar 

  2. Ryan, D. H. et al. Nat. Med. https://doi.org/10.1038/s41591-024-02996-7 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Colhoun, H. M. et al. Nat. Med. https://doi.org/10.1038/s41591-024-03015-5 (2024).

    Article  PubMed  Google Scholar 

  4. Kivimäki, M. et al. Lancet Diabetes Endocrinol. 10, 253–263 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lean, M. E. et al. Lancet. 391, 541–551 (2018).

    Article  PubMed  Google Scholar 

  6. Kosiborod, M. N. et al. N. Engl. J. Med. 389, 1069–1084 (2023).

    Article  CAS  PubMed  Google Scholar 

  7. Sattar, N. et al. Lancet Diabetes Endocrinol. 9, 653–662 (2021).

    Article  CAS  PubMed  Google Scholar 

  8. Rossing, P. et al. Nephrol. Dial. Transplant. 38, 2041–2051 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Chang, A. R., Grams, M. E. & Navaneethan, S. D. Kidney Int. Rep. 2, 261–270 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Yau, K., Dharia, A., Alrowiyti, I. & Cherney, D. Z. I. Kidney Int. Rep. 7, 1463–1476 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Marx, N., Husain, M., Lehrke, M., Verma, S. & Sattar, N. Circulation. 146, 1882–1894 (2022).

    Article  CAS  PubMed  Google Scholar 

  12. Sattar, N., McMurray, J. J. V., McInnes, I. B., Aroda, V. R. & Lean, M. E. J. Lancet Diabetes Endocrinol. 11, 58–62 (2023).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Naveed Sattar.

Ethics declarations

Competing interests

N.S. reports consulting/speaker honoraria from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Novartis, Menarini-Ricerche, Novo Nordisk, Pfizer, Roche Diagnostics and Sanofi, along with grants paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics. M.M.Y.L. has received research grants through his institution, the University of Glasgow, from AstraZeneca, Boehringer Ingelheim and Roche Diagnostics and is a member of a trial steering committee for Cytokinetics and of a clinical endpoints committee for Bayer. D.K.M. reports research support for clinical trials leadership from Boehringer Ingelheim, Pfizer, AstraZeneca, Novo Nordisk, Esperion, Lilly USA and CSL Behring, as well as honoraria for consultancy from Lilly USA, Pfizer, Boehringer Ingelheim, Lexicon, Novo Nordisk, Applied Therapeutics, Altimmune, CSL Behring, Bayer, Intercept and New Amsterdam.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sattar, N., Lee, M.M.Y. & McGuire, D.K. What the SELECT trial of semaglutide means for clinicians. Nat Med (2024). https://doi.org/10.1038/s41591-024-03013-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41591-024-03013-7

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing